MC1R

MC1R is the class A GPCR on melanocytes that controls the eumelanin/pheomelanin switch - the master determinant of skin and hair pigmentation, UV photoprotection, and melanoma risk. It is the sole approved clinical target in the melanocortin receptor family: afamelanotide (NDP-α-MSH) is FDA-approved for erythropoietic protoporphyria (EPP). MC1R also modulates pain sensitivity, inflammation, and DNA repair independently of pigmentation, expanding its therapeutic relevance beyond dermatology. Every scaffold targeting photoprotection, EPP, pigmentation disorders, or melanocortin anti-inflammatory biology routes through this card.

Receptor structure and signaling

MC1R (chromosome 16q24.3, 317 aa, intronless gene) adopts the canonical class A GPCR seven-TM architecture. The ligand-binding orthosteric pocket is formed by TM2 (Glu94), TM3 (Asp117, Asp121), TM5, TM6, and ECL2, which coordinate the conserved His-Phe-Arg-Trp (HFRW) core motif shared by all melanocortin peptides (α-MSH, β-MSH, γ-MSH, ACTH). α-MSH (EC₅₀ ~2 pM for cAMP in melanocytes) drives primary signaling: Gs → adenylyl cyclase → cAMP → PKA → CREB phosphorylation → MITF upregulation → tyrosinase/TRP-1/TRP-2 gene expression → eumelanin synthesis. Parallel: β-arrestin/ERK for proliferation and anti-apoptotic signaling; cAMP/PKA → ATR phosphorylation → enhanced nucleotide excision repair (NER) after UV damage. Endogenous antagonists agouti signaling protein (ASIP) and β-defensin 3 compete at the orthosteric site and act as inverse agonists, suppressing basal cAMP and shifting output to pheomelanin. MC1R shows partial constitutive activity - relevant to baseline eumelanin tone. The >100 identified MC1R variants include loss-of-function alleles R151C, R160W, and D294H (red hair, fair skin, impaired DNA repair, elevated melanoma risk) and rare activating mutations that cause familial melanoma-associated hyperpigmentation.

Approved drugs and research recipes

Afamelanotide (NDP-α-MSH; [Nle⁴, D-Phe⁷]-α-MSH), a potent, DPP-4-resistant α-MSH analog, is approved in the EU and USA for EPP - subcutaneous implant every ~60 days increases photoprotection by driving constitutive eumelanin production. Dersimelagon (MT-7117, oral small molecule) is in Phase 3 for EPP and polymorphous light eruption. BMS-470539 (selective MC1R small-molecule agonist, 90-fold selective over MC3R/MC4R) provides the pharmacophore template for anti-inflammatory applications. For peptide research, the tractable recipes are: NDP-α-MSH analogs with C-terminal PEGylation or fatty acid conjugation for depot-free extended-release SC dosing in EPP; cyclic lactam-constrained α-MSH analogs (ring closure between positions 4–9) for subtype-selective MC1R agonism with reduced MC4R cross-reactivity; Ac-His-D-Phe-Arg-Trp-NH₂ minimum pharmacophore variants for topical delivery in sunless tanning or vitiligo applications; and biased MC1R agonists that preferentially activate PKA/MITF/NER over β-arrestin/ERK to maximize photoprotective DNA repair without driving melanocyte proliferation.